Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Dar Global

    MCap

    USD1,486m

    Last close

    USD8.25

    ▲ −0.25 (−2.94%)

    Theon International

    MCap

    EUR875m

    Last close

    EUR12.50

    ▲ 1.44 (13.02%)

    Metals One

    MCap

    GBP2m

    Last close

    GBP0.00

    ▲ 0.04 (8.89%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Incannex Healthcare: Disrupting the obstructive sleep apnoea space with IHL-42

Incannex Healthcare: Disrupting the obstructive sleep apnoea space with IHL-42

Incannex Healthcare — 1 video in collection

More on this equity

Incannex Healthcare (Nasdaq: IXHL, ASX: IHL) is an Australian biotech specialising in the development of treatments for chronic conditions using cannabinoids and psychedelic therapies.

Incannex has 28 clinical programmes in progress and holds one of the world’s largest portfolios of patented cannabinoid drug formulations and psychedelic treatment regimes.

The company’s most advanced clinical asset, IHL-42X, is being developed for the treatment of obstructive sleep apnoea and will see bioavailability and bioequivalence studies roll out in 2023.

Watch Dr Mark Bleackley, Incannex’s chief scientific officer, and Joel Latham, the company’s MD and CEO, being interviewed by Vivienne Parry, to find out more about IHL-42X and Incannex Healthcare’s investment case.

< Previous
Next >

You may also be interested in these:

Healthcare

Mendus – executive interview

Healthcare

Oryzon Genomics – executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free